Published in J Prev Med Hyg on June 01, 2013
Meta-analysis of associations of interleukin-28B polymorphisms rs8099917 and rs12979860 with development of hepatitis virus-related hepatocellular carcinoma. Onco Targets Ther (2016) 0.82
Combined Effects of 2 Interleukin 28B Polymorphisms on the Therapeutic Outcome of Hepatitis C Patients With Circulating Cryoglobulins. Medicine (Baltimore) (2015) 0.75
Genetic predictors of the response to the treatment of hepatitis C virus infection. Bosn J Basic Med Sci (2015) 0.75
Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients. J Biomol Tech (2016) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Global epidemiology of hepatitis C virus infection. Lancet Infect Dis (2005) 16.44
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol (2012) 14.55
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Course and outcome of hepatitis C. Hepatology (2002) 6.51
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat (2006) 5.10
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
Natural history of hepatitis C. Clin Liver Dis (2005) 3.34
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Host genetic factors and antiviral immune responses to hepatitis C virus. Clin Liver Dis (2008) 1.79
Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2010) 1.73
IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol (2010) 1.64
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol (2011) 1.45
Host genetic determinants in hepatitis C virus infection. Genes Immun (2004) 1.44
Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol (2005) 1.33
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol (2010) 1.18
Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis (2007) 1.08
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology (2009) 0.92
Pharmacogenetics of hepatitis C. J Antimicrob Chemother (2011) 0.87
The intradermal vaccination: past experiences and current perspectives. J Prev Med Hyg (2010) 0.87